Pam joined Genocea in July 2016 as Senior Vice President, Immuno-oncology. Here, she leverages her expertise in cancer biology and immuno-oncology to guide the development and strategic direction of Genocea’s oncology pipeline. Pam’s previous positions include Vice President of Oncology Discovery at Roche Pharma Research and Early Development, Vice President of Janssen oncology at Johnson and Johnson Innovation, and founding Head of Research at the Belfer Institute for Applied Cancer Science at Dana Farber Cancer Institute. Her broad skillset also comes from drug discovery experience working in applied genomics at Bristol-Myers Squibb and oncology research done at Merck Research Laboratories. Pam earned a B.A. in biology at St. Michael’s College in Vermont, a doctorate in cellular biology at Stony Brook University, and completed a post-doctorate fellowship at Stanford University.
Chip has served as our President and Chief Executive Officer since February 2011 after serving as our Chief Business Officer from August 2010 to February 2011. Chip has also served on our board of directors since February 2011. Prior to joining Genocea, he served as Chief Business Officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities and played a central role in raising more than $400 million through business development deals and equity financings. Prior to Vanda, Chip was a principal at Care Capital, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.
Tom joined Genocea in October 2018 as Chief Medical Officer with 20+ years of academic and industry experience in immuno-oncology and cancer drug development. Most recently, he served as Chief Medical Officer of Gadeta B.V., a Dutch cell therapy company pursuing novel cancer targets, where he steered a novel cell therapy technology into first-in human clinical studies. He previously served as Chief Medical Officer of Celldex from 2006 to 2017, where he led all aspects of clinical and regulatory development including strategy, tactics, and execution. While at Celldex, Tom actively built and oversaw Clinical Science, Medical Affairs, Safety, Clinical Operations, Statistics, Regulatory Affairs, and Project Management, managed collaborations with large global pharmaceutical partners, and participated in investor relations activities. He also served as Chief Medical Officer at GenVec and as Senior Director of Clinical Science at Medarex.
Prior to joining the industry, Tom supervised clinical efforts at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), and worked on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, his M.S. in Physiology and his M.D. from Georgetown University, and completed a fellowship in medical oncology at Stanford University.
Jess joined Genocea in 2007, soon after the company was founded, and currently serves as Chief Scientific Officer. She is widely recognized as a pioneer in the development of novel vaccines directed toward T cell immunity and has more than 20 years of experience in immunology, cancer, infectious disease, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against cancer using the company’s proprietary ATLAS platform to identify and characterize both common and personalized antigens. Prior to joining Genocea, Jess served in a variety of roles developing vaccines and immunotherapies for cancer, infectious disease, autoimmunity, and allergy at companies including Mojave Therapeutics and Antigenics (now Agenus). Jess received a B.S. in Animal Science and a Ph.D. in Cellular Immunology from Cornell University, and performed her post-doctoral work at Dana Farber Cancer Institute and Harvard Medical School. She is a member of Women in Bio, the American Association of Immunologists, the American Association for Cancer Research, the Society for Immunotherapy of Cancer, the President’s Council of Cornell Women, and the American Society for Microbiology. She is also an inventor on numerous pending and issued patents and is the author of multiple peer-reviewed scientific publications.
Derek joined Genocea in September 2018 as Senior Vice President and General Counsel. In this role, Derek manages Genocea's legal affairs and advises the company on business strategy and implementation. He has extensive experience as a corporate attorney, serving for several years as the General Counsel to multiple Boston-based financial services firms, including a prominent biotechnology investment firm. Derek also previously served as Partner at the international law firm of K&L Gates, where he counseled various corporate clients on corporate governance, regulatory, and compliance matters, and as a Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission. Derek earned a B.A. from The University of Michigan and a J.D. from The American University, Washington College of Law.
Narinder Singh joined Genocea in March 2018, and currently serves as senior vice president, Pharmaceutical Sciences and Manufacturing. Narinder has more than 20 years of experience in process development, scale-up, technical operations, and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Narinder served as vice president of Drug Product Development and Manufacturing at Momenta Pharmaceuticals, where he built an integrated drug product group to support Momenta’s expanding portfolio of biosimilars and novel biologics. Prior to Momenta, he held positions at Amgen, where he played a key role in development of Amgen’s biologics-based pipeline and commercial drug products with a strong focus on process development, commercialization, manufacturing, and new technology development. Narinder holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from Indian Institute of Technology, Delhi, an M.S. in Chemical Engineering from the University of Houston, and an M.B.A. from UCLA Anderson School of Management.